Ashley Chan's profile photo

Ashley Chan

New York

Assistant Editor at CURE Magazine

Featured in: Favicon curetoday.com Favicon huffpost.com Favicon yahoo.com Favicon apnews.com Favicon thestar.com Favicon theglobeandmail.com Favicon usnews.com Favicon europapress.es Favicon globalnews.ca Favicon seattletimes.com

Articles

  • Bendamustine/Rituximab Represents a Backbone for Therapeutic Development in MCL

    6 days ago | onclive.com | Ashley Chan

    The combination of bendamustine and rituximab (Rituxan; BR) as induction therapy with bortezomib (Velcade) did not demonstrate improved 2-year progression-free survival (PFS) vs BR alone in patients with mantle cell lymphoma (MCL), according to data from the phase 2 ECOG-ACRIN E1411 trial (NCT01415752).1 However, the notable 2-year PFS outcomes with BR alone have paved the way for a standard to build upon in the MCL treatment landscape, according to Brad S. Kahl, MD.

  • SOC Encorafenib/Binimetinib Sets a Precedent for Therapeutic Improvements in BRAF V600E-Mutant NSCLC

    1 week ago | onclive.com | Ashley Chan

    CommentaryArticleMay 9, 2025Fact checked by:Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm. Within the past 3 years, the BRAF V600E–mutant NSCLC treatment arsenal has seen positive shifts toward improved standards of care [SOC] following the FDA approvals of dabrafenib plus trametinib and encorafenib plus binimetinib, according to Joseph C.

  • Adavosertib Shows Early Antitumor Activity Despite Safety Concerns in Uterine Serous Carcinoma

    1 week ago | onclive.com | Ashley Chan

    The WEE1 inhibitor adavosertib (AZD1775) demonstrated preliminary antitumor activity in heavily pretreated patients with advanced recurrent/persistent uterine serous carcinoma, although the agent was not well tolerated when administered at 300 mg once daily, according to Data from the phase 2b ADAGIO trial (NCT04590248), which were published in the Journal of Clinical Oncology.1 The findings revealed that in patients from the full analysis set, the objective response rate (ORR) among patients...

  • ADCs and PARP Inhibitors Are Among 2025’s Practice-Changing Agents in Ovarian Cancer

    1 week ago | onclive.com | Ashley Chan

    Since the December 2014 FDA approval of the PARP inhibitor olaparib (Lynparza) for the treatment of patients with BRCA-mutant advanced ovarian cancer, the respective treatment landscape has seen immense developments, from targeted therapies like PARP inhibitors to antibody-drug conjugates (ADCs), according to Deena M.

  • Nivolumab/Ipilimumab Meets Primary OS End Point in Non-Clear Cell RCC

    1 week ago | onclive.com | Ashley Chan

    Nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrated significantly longer 12-month overall survival (OS) with an acceptable safety profile for the treatment of patients with non–clear cell renal cell carcinoma (nccRCC) compared with standard of care (SOC), meeting the primary end point of OS, according to data from the phase 2 SUNNIFORECAST trial (NCT03075423).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →